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We report a thirteen-year-old tennis player with knee hemarthrosis caused by low factor XIII activity. She visited our
hospital because of medial peripatellar pain for two years. Although there was no abnormal sign in X-ray or MRI,
diagnostic arthroscopy was performed. It revealed some cartilage debris, medial plica and complete septum of
suprapatellar plica. Removing the debris by washing out and resecting the medial plica, she could return to play
tennis without perioperative symptom. Two months after the first operation, her knee got swelling without any
apparent cause. Since 20 ml blood was aspirated twice and MRI revealed suprapatellar mass, we performed
arthroscopy again. Suprapatellar mass was old blood clot covered with complete suprapatellar plica. Resection of
suprapatellar plica and washing out blood clot were performed, and severe postoperative hemarthrosis was
progressively occurred. As factor XIII level was 54% preoperatively, we diagnosed that this condition was caused by
low activity level of the factor and administered factor XIII concentrates. The level got improved to 129% and then
hemarthrosis gradually relieved. She had no signs of recurrence. We should keep in mind of low factor XIII activity
case in case of unexplained postoperative hemarthrosis after arthroscopy because consumption of the factor might
promote this condition.Background
Hemarthrosis is one of the most common complications
after knee arthroscopy [1]. Hemarthrosis is generally not
severe except in coagulation factor deficiency. In case of
hemophilia this complication is critical, and standard
coagulation studies can reveal this disorder. But deficiency
of factor XIII cannot be suggested with those studies.
Therefore, it is necessary to test factor XIII activity or clot
solubility test for diagnosing this disorder. Factor XIII is
known as fibrin stabilizing factor, which acts in the
terminal phase of the coagulation cascade. The disorder
presents clinically with bleeding diathesis, and impaired
wound healing. Congenital deficiency of factor XIII was
first described in 1960 by Duckert [2] and acquired
deficiency of the factor was also reported in some articles
[3-5]. However, there are few literatures associated with
deficiency of factor XIII especially in the field of ortho-
pedic surgery [6]. We here present a case of postoperative
hemarthrosis caused by low activity level of this factor.* Correspondence: s-horibe@rehab.osakafu-u.ac.jp
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A thirteen-year-old junior tennis player, who had had no
past history of disorder and played several hours a day
since 6 years old, visited our hospital with the chief com-
plaint of left knee pain after tennis games for two years.
She had a medial peripatellar pain and knee flexion angle
was slightly restricted. Although X-ray and MRI revealed
no abnormal findings, we performed diagnostic arthros-
copy because she and her parents had strong desire to re-
ceive arthroscopic inspection. Arthroscopy showed that
the ACL and menisci were intact, but there were some car-
tilage debris. In addition, there were the medial plica and
the suprapatellar plica (plica synovialis suprapatellaris,
PSSP) with a complete septum, then the debris was washed
out and the medial plica was resected. Her knee flexion
angle got improved postoperatively, followed by return to
the tennis court. Two months after the operation, her left
knee got swelling after a long distance walk. Approximately
20 ml of bloody effusion was aspirated by joint puncture
twice, and after this procedure the knee swelling increased.
T2 weighted MR images revealed high intensity mass in
the suprapatellar pouch, indicating of hematoma (Figure 1).
As knee flexion angle was gradually restricted again to
110o, we decided to perform arthroscopic removal of thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 T2 weighted MR image shows high intensity mass in
the suprapatellar pouch (arrows).
Figure 2 Bloody content flowed out from suprapatellar pouch
(arrow).
Table 1 Changes of Hemoglobin (g/dl) and XIII activity (%)
Pre POD 7 POD 8 POD 9 POD 13 PO 3mo
Hemoglobin (g/dl) 13.5 10.3 10.8 10.6 10.8 13.1
XIII activity (%) 54 - 98 129 - 57
* Factor XIII concentrates administered on postoperative days (POD) 7, 8, and 9.
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hematoma, we examined factor XIII preoperatively and the
level was 54% which was slightly low (normal; over 70%),
with no abnormal findings in the standard coagulation
studies. At arthroscopy, there was no bloody effusion or
hemosiderin deposit within the joint, but in the proximal
side of PSSP complete septum there seemed to be blood
like content. Resecting the septum with shaver, old blood
clot was flowed out (Figure 2). Complete resection of the
septum and old blood clot was performed as possible. On
the next day, there was no bleeding from the wound and
total drainage volume was 90 ml, then we removed the
drainage tube. However, her knee got swelling progres-
sively and the flexion angle was severely restricted to 30o.
Hemoglobin was decreased from 13.5 g/dl preoperatively
to 10.3 g/dl on postoperative days (POD) 7 and blood loss
estimated to about 800 ml [7]. After discussion with a
hematologist, we diagnosed that this condition was caused
by low activity level of factor XIII and administered factor
XIII concentrates on POD 7 to 9. The level got improved
to 129% and then the knee swelling gradually relieved
(Table 1). After 3 months postoperatively, she returned to
play tennis and after 5 months she completely returned to
the game. There was no recurrence but the level of factor
XIII returned to preoperative level (57%), which was slight
low, three months after the second operation.Discussion
We presented a case of severe knee hemarthrosis after
knee arthroscopy. Although hemarthrosis is one of the
most common complications after knee arthroscopy [1],
it is generally not severe and often relieved sponta-
neously, except in coagulation factor deficiency. In case
of hemophilia, which deficit factor VIII or IX, this com-
plication is critical, and preoperative standard coagula-
tion studies can reveal this disorder. But deficiency of
factor XIII cannot be suggested with the standard coagu-
lation examination, including prothrombin time, partial
prothrombin time, thrombin time, bleeding time, platelet
count, and qualitative platelet function assays. Therefore,
it is necessary to test factor XIII activity or clot solubility
test for diagnosing this condition.
Factor XIII, also known as fibrin stabilizing factor, is an
enzyme required for normal fibrin clot formation. It acts in
the terminal phase of the coagulation cascade, after throm-
bin has converted fibrinogen to fibrin. In the absence of
factor XIII a clot is easily soluble, so its deficiency leads to
prolonged bleeding which is characteristically delayed 12–
36 h after stop bleeding. Congenital deficiency of factor XIII
was first described in 1960 by Duckert [2]. The disorder
presents clinically with bleeding diathesis, and impaired
wound healing. And it is also reported about acquired defi-
ciency of factor XIII, caused by formation of antibody or
unknown reason [3-5]. According to the European data,
the most common bleeding symptoms were subcutaneous
bleeding, muscle hematoma, hemorrhage after surgery,
hemarthrosis, and intracerebral bleeding [8]. Decreased
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unexplained intraoperative and/or postoperative hematoma
in abdominal, gynecological, plastic, and urological surgery
and also recently in the field of neurosurgery [9]. To the
best of our knowledge, however, there were few literatures
about periarticular hematoma due to factor XIII deficiency
or decreased activity level of factor XIII during periopera-
tive phase. In this present case, low activity level of the fac-
tor seemed to be the cause of unexplained bleeding. As its
concentration was recovered by administering the factor
XIII concentrates, it was highly unlikely that the condition
was associated to autoimmune antibody. In addition to the
preoperative low activity level, consumption of the factor
was likely to aggravate bleeding diathesis. As described by
Korte, acquired factor XIII deficiency in the perioperative
setting might be frequent [10]. Furthermore, Spahn demon-
strated that blood loss could be reduced with administra-
tion of a single dose of factor XIII given within 15 min
commencement of surgery [11].
As for perioperative level of factor XIII, no report has
clearly revealed when we should administer factor XIII
concentrates. In general, it is considered sufficient to keep
10% in small bleed, or 20-30% in muscle hematoma. But
in severe bleeding case or major surgery, increasing use of
the factor in the wound, it is recommended to keep 100%
preoperatively [12]. Gerlach et al. reported the average
postoperative decrease in factor XIII was approximately
18% in the neurosurgery patients [9]. Furthermore, they
concluded the risk of postoperative hematoma is increased
in patients with factor XIII < 60%. Taking the conclusion
into account, the perioperative low activity level of factor
XIII might have been the risk of the hemarthrosis follow-
ing arthroscopy.Conclusion
We report a case of postoperative hemarthrosis caused
by low factor XIII activity. Decreased activity of the fac-
tor seemed to be the cause, and the consumption might
have an effect on bleeding diathesis. We should be in
careful about managing this condition perioperatively as
coagulation factor activity can decrease by increasing
consumption of the factor.Consent
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